Trial
NCT00486980
Intramuscular Peramivir for the Treatment of Uncomplicated Influenza
Phase IIIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
BioCryst Pharmaceuticals
Collaborators
—
Condition
Influenza
Intervention
Peramivir 150mg
Why stopped
This study was withdrawn for administrative reasons. The dose ranging plan for the program was revised".
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-06-01